

**EB** RESEARCH
PARTNERSHIP[\(https://www.ebresearch.org/\)](https://www.ebresearch.org/)

**Q1
2023
Grants
Cycle
(/login?
return
Url=%2
Fsubmit
t%2F24
8847%
2Fq1-
2023-
grants-
cycle)**

Ends on
March 8,
2023

[Guidelines ^](#)[Apply > \(/login?returnUrl=%2Fsubmit%2F248847%2Fq1-2023-grants-cycle\)](#)

EB Research Partnership (EBRP), a 501(c)(3) non-profit organization, awards grants for research projects with the potential to lead directly to commercially feasible products and therapies for treating and/or curing Epidermolysis Bullosa (EB).

Process

Applicants are invited to submit an application via EBRP's grants management system. Applications will be evaluated and scored by EBRP's [Scientific Advisory Board \(SAB\)](https://www.ebresearch.org/scientific-advisory-board.html) (<https://www.ebresearch.org/scientific-advisory-board.html>). Based on the SAB's evaluation and scoring of applications and other criteria, EBRP's Executive Board will select specific projects for funding. Upon approval and if not already in place, EBRP will establish research contracts with the appropriate host institution(s). Any request by EBRP for additional information should not be considered as a Notice of Grant Award, nor should it be construed as an indicator of possible award. Grants awarded will be subject to [EBRP Grant Guidelines](https://www.ebresearch.org/uploads/1/0/4/4/104465755/ebprgrantguidelines2021.pdf) (<https://www.ebresearch.org/uploads/1/0/4/4/104465755/ebprgrantguidelines2021.pdf>), including a 5% limit on indirect costs. EBRP employs a venture philanthropy model for all funded projects, unless a specific waiver is granted for a highly specific reason. We also require documentation of Humane Care and Use of Laboratory Animals and documentation of Human Subjects approvals, whenever necessary.

EB Research Partnership abides by a [Whistleblower Policy](https://www.ebresearch.org/uploads/1/0/4/4/104465755/ebpr_-_whistleblower_policy_dec_2018_.pdf) (https://www.ebresearch.org/uploads/1/0/4/4/104465755/ebpr_-_whistleblower_policy_dec_2018_.pdf) and Anti-Corruption Policy.

Criteria

Research projects submitted for review:

- Should be designed to result in the creation of EB therapies with the aim of commercialization within the next 1-4 years. Approaches that lead to meaningful step changes in the quality of lives of those living with EB and/or aim to be curative will be prioritized. All approaches must include thoughts around commercial sustainability.
- May relate to repurposing existing drugs or products for EB, if expected to significantly impact EB patients' quality of life
- May be intended to provide localized or systemic benefit to EB patients.
- May involve pre-clinical or clinical trial work. However, clinical trial work is strongly preferred. Projects involving pre-clinical work should include a detailed plan and timeline regarding commercialization.
- May relate to developing research-enabling tools, such as data collection and analysis platforms, to accelerate clinical trials.
- Should not be concerned primarily with basic or open-ended research projects without the intention to lead directly to commercially feasible EB therapies.

Grants awarded will provide project funding for 1 year. Multi-year research applications should include a proposed timeline and milestones with budget. Depending upon the success of the initial year's activity and availability of future funding, there is potential for grants to be renewed annually for up to 5 years.

Q1 2023 Grant Cycle

EBRP expects to review applications for future funding cycles semiannually. The application deadline for this funding cycle is March 7, 2023 at 11:59 PM EST. The SAB will then evaluate and score the submitted LOIs, after which applicants will be contacted with the results. Applications must be submitted through this grants management platform.